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Abstract
The pericardium is a double-walled, fibrous sac typically containing 20–50 mL 
of fluid surrounding the heart and great vessels. In addition to its known anatomical 
and physiological functions, the pericardium also serves an active immunological 
role that is the focus of interest pertaining to inflammatory cardiac conditions such 
as pericarditis and myocarditis. In the geriatric population, the pericardium also 
undergoes age-related changes similar to other anatomical structures; however, in 
contrast to common cardiac diseases such as coronary artery disease, heart failure, 
valvular disease, etc., data from randomized trials regarding the management of 
pericardial diseases are limited, especially in the elderly population. In this chapter, 
we will discuss age-related pericardial anatomical changes, various pericardial 
diseases (acute, recurrent and constrictive pericarditis, pericardial effusion, cardiac 
tamponade, etc.) along with their clinical impact, and evidence-based management.
Keywords: pericardial disease, elderly, acute pericarditis, constrictive pericarditis, 
recurrent pericarditis, cardiac tamponade, pericardium, myocarditis
1. Age-related pericardial anatomical changes
The pericardium is subject to age-related changes just like any other organ in the 
human body although available literature regarding pericardial anatomy and peri-
cardial disease etiology related to aging is very limited. One study examining bovine 
pericardium for age-dependent differences in collagen alignment showed higher 
elasticity, higher tensile strength, and thin pericardium in neonatal compared to 
adult bovine pericardium [1]. Despite such noted anatomical changes in the pericar-
dial structure with age, the spectrum of pericardial disease remains similar among 
younger and older populations. Although most guidelines have not discussed 
specific age-related pericardial disease management, diagnostic evaluation and 
treatment of pericarditis in the geriatric population should take comorbidities into 
consideration for optimal management [2].
2. Pericardial effusion
The pericardial space contains 20–50 mL of fluid in the pericardial sac which 
works as a lubricant between two layers of pericardium. Pericardial effusion is 
defined by an excess fluid collection over the normal physiological amount within 
this space. Pericardial fluid accumulation can be secondary to increased fluid 
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production (i.e., any inflammatory condition) or from reduced fluid reabsorption 
(i.e., heart failure, pulmonary hypertension, and pericardial lymphatic obstruc-
tion). The fluid starts accumulating according to gravitational forces, initially in 
the posterior-inferior site then circumferentially resulting in moderate to large 
effusion.
Pericardial effusion can be classified based on various characteristics such as 
size (mild, moderate, and large), onset (acute, subacute, and chronic), distribution 
(localized or circumferential), composition (transudate, exudate, blood, or rarely 
gas from bacterial infections), and hemodynamic effects (without tamponade, with 
tamponade, effusive-constrictive) [2, 3]. (Table 1).
The normal pericardium is made up of a high content of collagen fibers, which 
creates a relatively inelastic sac that contains the heart. The pressure-volume curve 
of the normal pericardium is a J-shaped curve, which allows a limited stretch of the 
pericardium in response to physiological events such as posture or volume status 
without significant change in the intrapericardial pressure; however, after reaching 
a certain intrapericardial volume, the intrapericardial pressure rises suddenly and 
can cause sudden systemic hemodynamic derangements. The rapid rate of the fluid 
collection also plays a role in the pressure-volume curve; a sudden rise in intraperi-
cardial volume (such as with aortic dissection or trauma with hemopericardium) 
of 100–200 mL significantly raises the intrapericardial pressure, whereas the slow 
collection of fluid may allow the development of a large pericardial effusion (1–2 L) 
without signs of cardiac tamponade [3, 4].
2.1 Etiology
Among the elderly, the spectrum of etiologies for pericardial effusion does not 
differ significantly from the rest of the population. The underlying cause of effu-
sion can usually be inferred from the clinical picture. One study in 322 patients 
Size of fluid collection in TTE* Less than 10 mm—mild
10–20 mm—moderate
More than 20 mm—large















Classification of pericardial effusion.
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has reported around 60% of cases had a known cause of pericardial effusion [5]. 
A varying amount of effusion can be seen in other conditions such as malignancy 
(with or without direct pericardial involvement), renal failure, pregnancy, aortic or 
cardiac wall rupture, trauma, heart failure, cirrhosis of the liver, nephrotic syn-
drome, autoimmune diseases, radiation, etc. One study incorporated demographics 
in their review of pericarditis etiology by comparing a younger patient population 
(age 15–65, n = 221) to a geriatric population (age 66–88, n = 101) and found no 
statistically significant differences in the incidence of idiopathic (33 vs. 38%) 
versus neoplastic (14.4 vs. 10.8%) pericarditis or the incidence of tamponade (36 vs. 
38.6%) [6]. The cause of effusion may also vary by geographical area and clinical 
setting. For example, effusions related to viral pericarditis or idiopathic pericarditis 
are more common in outpatient populations of the western world, whereas bacte-
rial and tuberculous inflammation and effusion are more common in sub-Saharan 
Africa and the developing world. Effusions associated with uremic pericarditis or 
malignancies are frequently found in hospital settings [3, 7].
According to one study with a mean participant age of 56, when determining the 
cause of moderate to severe pleural effusions, it is important to consider three major 
factors: (1) size of effusion; (2) presence of tamponade; and (3) inflammatory signs 
(defined as two or more from: fever >37°C, pericardial friction rub, characteristic 
chest pain, and diffuse ST-segment elevation). The presence of inflammatory signs 
was associated with acute idiopathic pericarditis (likelihood ratio = 5.4, P < 0.001), 
a large effusion without any inflammatory signs or tamponade was found to be 
associated with chronic idiopathic pericardial effusion (likelihood ratio = 20, 
P < 0.001), and the features of tamponade without inflammatory signs were associ-
ated with malignant effusions (likelihood ratio = 2.9, P < 0.01) [5].
2.2 Clinical presentation
The presentation of pericardial effusion varies according to the speed of accu-
mulation, size of effusion, and etiology. The rate of fluid collection plays a critical 
role in clinical presentation as rapidly accumulating pericardial effusion causes a 
quick rise in intrapericardial pressure, which results in cardiac tamponade, while 
slowly accumulating fluid accommodates comparatively larger volume before signs 
of tamponade [2, 3]. The cases of isolated pericardial effusion can be asymptomatic 
or can have symptoms related to the underlying etiology or to the effusion itself. 
The classically reported symptom is dyspnea on exertion; however, the wide 
spectrum of symptoms related to compressive effect includes cough, weakness, 
fatigue, palpitations (from compressive effect of the pericardial fluid or reduced 
blood pressure), nausea (diaphragm), dysphagia (esophagus), hoarseness of voice 
(recurrent laryngeal nerve), etc. Patients may present with fever from underlying 
disease (infectious or systemic inflammatory disease), pleural effusion, ascites, or 
hepatic dysfunction from long standing pericardial constriction [2, 8].
Physical examination may remain normal without any significant findings in 
patients with no hemodynamic compromise. Pulsus paradoxus is an inspiratory drop 
in systolic BP >10 mmHg due to the augmentation of right ventricular preload causing 
impaired left ventricular filling resulting in abnormal decrease in stroke volume [9] 
and is a phenomenon commonly seen with large pericardial effusion or cardiac tam-
ponade. Pericardial friction rub is rarely heard but is a usual finding of pericarditis.
2.3 Diagnostics
Upon clinical suspicion of pericardial effusion, the diagnostic approach 
should consider three major steps: (1) confirm the presence of effusion; (2) 
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assess the hemodynamic impact; and (3) effort to identify the underlying etiol-
ogy. Transthoracic echocardiography (TTE) is recommended in all patients with 
suspected effusion as a class I, level C recommendation. Further imaging modalities 
such as computed tomography (CT) scan, cardiac magnetic resonance imaging 
(CMRI), pericardial fluid analysis, or biopsy can be considered in cases where 
loculated effusion, masses, or thickening of the pericardium are suspected. Basic 
diagnostic work up, including blood counts, chemistry, thyroid function tests, 
cardiac biomarkers, inflammatory markers such as C-reactive protein (CRP) and 
sedimentation rate (ESR), electrocardiogram (ECG), and chest X-ray, should be 
done [2, 10]. ECG findings in pericardial effusion include low QRS voltage and 
electrical alternans, a finding of large pericardial effusion or tamponade that is 
usually associated with sinus tachycardia.
TTE is recommended as the first modality to determine the hemodynamic 
significance of pericardial effusion and is highly sensitive and specific. The 
pericardial fluid appears as echo-lucent space between the pericardium and 
epicardium on TTE. The semi-quantitative assessment for largest echo-free space 
in echocardiographic views provides an assessment of severity. Mild pericardial 
effusion is considered <10 mm, moderate between 10 and 20 mm, and large effu-
sion is any collection >20 mm. The collection of effusion follows gravity initially 
in the inferolateral position close to right atrium in the apical four chamber view 
with the patient in a supine-left lateral position. The pattern of collection changes 
to circumferential in the pericardium with increasing amount of fluid (Figure 1). 
After the development of a large amount of effusion, the heart can be seen swing-
ing in the pericardial cavity, a finding that correlates with electrical alternans on 
ECG [2, 3, 11].
Cardiac CT and CMRI are useful imaging modalities for the evaluation of 
pericardial effusion and tamponade especially for more detailed assessment and the 
localization of the effusion and associated abnormalities in the mediastinum, lungs, 
Figure 1. 
Large circumferential pericardial effusion.
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and adjacent structures. They are useful for the guidance of pericardiocentesis since 
loculated effusions or calcified pericardium can be identified. CMRI is superior 
to CT in differentiating fluids especially highly exudative fluid from thickened 
pericardium. CT detects a minimum amount of pericardial calcium and is relatively 
quick [2, 11].
Pericardial fluid analysis is often performed when the patient requires pericar-
diocentesis. Routine fluid studies include measuring fluid protein level, protein 
fluid/serum ratio, lactate dehydrogenase (LDH), LDH fluid/serum ratio, glucose, 
cell counts, and specific gravity. Fluid cytology and tumor markers (carcinoembry-
onic antigen, cancer antigen 19-9, adenosine deaminase, and interferon gamma) are 
useful measures in malignancy. Polymerase chain reaction and fluid cultures help in 
infectious etiologies.
2.4 Treatment
For small-to-medium sized, asymptomatic pericardial effusion without signs 
of hemodynamic instability, regular outpatient follow-up with clinical examina-
tion and/or echocardiography should be preferred. Management of pericardial 
effusion with signs of inflammation (pericarditis) should follow the standard or 
treatment for pericarditis; however, in the absence of any inflammation, anti-
inflammatory drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs), 
colchicine, and corticosteroids, are generally not effective. Such cases as well as 
cases with large effusion that failed empiric anti-inflammatory therapy would 
require pericardiocentesis. Recurrence of effusion is fairly common and further 
management options include pericardial window formation or pericardiectomy. A 
study comparing patients age 15–65 to a group of patients age 66–88 years showed 
elderly people had more persistence of effusion (6.3 vs. 14%; P < 0.05) but no sta-
tistically significant difference in mortality (24 vs. 30%) or evolution of cardiac 
constriction (4 vs. 2%) during median follow up time of 11 months [6]. There is 
no standard guideline available for elderly patients regarding pleural effusions; 
however, the expert consensus suggests adjusting the type and dosages of medi-
cations with special attention to drug interactions and renal function given the 
prevalence of polypharmacy and renal dysfunction in the geriatric population [2]. 
A proposed management algorithm for pericardial effusion of unknown origin is 
depicted in Figure 2 [2, 3].
2.5 Prognosis
The prognosis of pericardial effusion is related to its etiology and size. 
Moderate-to-large size effusions are more commonly associated with bacterial 
infection, systemic inflammatory disease, or malignancy. Idiopathic pericardial 
effusion has a good prognosis, but effusion related to bacteria, post-radiation, or 
pericardial injury has a higher rate of developing either early (cardiac tamponade) 
or late complications (constrictive pericarditis). Large effusion (>3 months) carries 
a 30–35% risk of progression to cardiac tamponade. The follow-up of pericardial 
effusion is mainly based on symptomatic evaluation with the follow-up of inflam-
matory biomarkers and echocardiography [3]. A recent meta-analysis regarding 
prognosis of pericardial effusion in an elderly population with mean age > 60 
reported that pericardial effusion can be considered as a marker of severity of the 
underlying disease as evidenced by a higher hazard ratio (HR) in patients with peri-
cardial effusion with myocardial infarction (HR 2.65, 95% CI: 1.4–4.99; P  =  0.003, 
15 months follow-up) versus those with chronic heart failure (HR 1.53, 95% CI: 




Acute pericarditis is a condition defined by the inflammation of the pericardial 
sac that can take place in the setting of a systemic disease (infectious, malignant, 
inflammatory, etc.) or independently of any other condition [2, 5, 13–15]. Among 
the elderly, it is important to consider malignancy in the evaluation of etiology as it 
is more common in this population and may prompt appropriate testing leading to a 
faster diagnosis and potential earlier intervention.
3.1 Etiology
Various infections (viral, bacterial, fungal, and tick-borne) have been known 
to cause the inflammation of the pericardium. In fact, prior to the widespread 
distribution of anti-retroviral medications, pericarditis was found to be the 
most common cardiovascular manifestation of human immunodeficiency virus/
acquired immunodeficiency syndrome [16, 17] and, in conjunction with tuber-
culosis, remains the most common cause of pericardial inflammation in the 
developing world [18], whereas coxsackievirus maintains its status as the most 
common viral etiology of pericarditis overall. Malignancy, independent of other 
systemic diseases, has also been associated with acute pericardial disease and 
Figure 2. 
Management algorithm for pericardial effusion with unknown origin.
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accounts for about 6% of cases without another explanation [19, 20]. Systemic 
diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis 
(RA), have been found to cause pericardial inflammation with approximately 
50% of patients with SLE experiencing pericarditis. Other established etiolo-
gies of acute pericardial disease include post-myocardial infarction pericardial 
inflammation and/or effusion [21–24], post-radiation pericarditis with or 
without pericardial effusion [25], and uremic pericarditis usually in the setting 
of advanced renal failure and inadequate dialysis [26, 27]. Hypothyroidism 
severe enough to result in myxedema can result in a large, slowly accumulating 
pericardial effusion but rarely causes acute pericarditis [28].
3.2 Clinical presentation
There are four major distinctive features of acute pericarditis (at least two of 
which are required to make a clinical diagnosis): chest pain, pericardial friction rub, 
characteristic ECG changes, and pericardial effusion. The predominant presenting 
symptom is chest pain that is usually pleuritic in nature, sharp and alleviated by sit-
ting up and leaning forward due to the positional shift of the pericardium, a feature 
which distinguishes it from the typical chest pain caused by myocardial ischemia 
[29, 30]. Pericardial chest pain is also often associated with nonproductive cough and 
dyspnea [29]. A scratchy, squeaking sound heard over the left sternal border upon 
auscultation known as a pericardial friction rub is the second of four major clinical 
features of pericarditis and is reported to be found in approximately 85% of patients 
with acute pericarditis in the absence of a pericardial effusion [20]. It is an extra 
heart sound resulting from the friction between the parietal and visceral pericar-
dium coming into contact in the presence of inflammation. The presence of a peri-
cardial effusion is the third of the four major signs of acute pericarditis and can best 
be appreciated on an echocardiogram. The last of the four major signs of pericarditis 
is new, diffuse ST-elevation, PR segment depressions, and PR segment elevation in 
lead aVR found on ECG (discussed further under Diagnostics) [15, 29, 31]. Other 
secondary features of pericarditis that may or may not be present are fever, subacute 
course of chest pain, elevated troponin (suggestive of myocardial involvement), and 
hemodynamic instability (suggestive of cardiac tamponade) [32, 33].
3.3 Diagnostics
Various laboratory tests and imaging modalities play role in establishing the 
diagnosis of acute pericarditis. Inflammatory markers, such as white blood cell 
count (WBC), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) 
levels although nonspecific, may help distinguish pericarditis from a condition with 
overlapping features given appropriate clinical criteria. Troponin levels, usually 
elevated in acute coronary syndrome, may also be elevated in pericarditis indicating 
myocardial involvement [34].
The chest X-ray may show cardiomegaly in the presence of a significant pericar-
dial effusion but otherwise has limited utility in the diagnosis of pericardial disease. 
An echocardiogram can be similarly useful although the absence of pericardial 
effusion would not necessarily exclude the diagnosis of acute pericarditis. Cardiac 
CT imaging can serve a dual purpose in the diagnosis of acute pericarditis in that it 
may also help elucidate the underlying pathology responsible for the inflammatory 
changes. Pericardial thickening and effusion in the absence of calcification along 
with the enhancement of the visceral and parietal pericardium with intravenous 
contrast are indicative of active inflammation consistent with pericarditis [35]. 
CMRI can confirm inflammation but is likely not necessary in the diagnostic 
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workup of acute pericarditis unless the presumed etiology is a systemic inflamma-
tory or autoimmune disease with characteristic cardiac findings.
The ECG may be perhaps the most useful diagnostic modality when consider-
ing acute pericarditis. The ECG progresses through a distinctive, four stage pat-
tern although the evolution can be variable with up to 40% of patients showing 
atypical changes [30–32]. Stage 1 is characterized by widespread ST elevation with 
reciprocal ST depression in leads aVR and V1 as well as PR segment elevation in 
lead aVR accompanied by PR segment depression in the remaining limb leads and 
V5–6. Within 1 week of onset, normalization of ST and PR segments on the ECG 
comprises Stage 2. Stage 3 of the ECG is marked by diffuse T-wave inversions, while 
Stage 4 consists of normalization of the ECG. However, not all forms of pericarditis 
result in the characteristic ECG pattern as the pericardium itself is an inert tissue 
and only inflammatory changes involving the epicardium or myocardium would be 
reflected in acute pericarditis [36]. In fact, one review found that of 100 patients 
studied, only seven arrhythmias were identified all resulting from underlying heart 
disease [37], while a separate study comparing acute pericarditis to myopericarditis 
found arrhythmias more frequently associated with myopericarditis [38].
3.4 Treatment
Medical treatment of acute pericarditis utilizes one or a combination of two out 
of three different medications: NSAIDs, colchicine, and glucocorticoids. Treatment 
duration is usually guided by the resolution of symptoms and etiology of disease in 
the absence of confounding factors such as acute kidney or liver injury.
A combination of NSAIDs and colchicine is the mainstay of therapy for acute 
viral or idiopathic pericarditis. NSAIDs alone have been shown through multiple 
studies to effectively treat up to 80% of pericarditis cases [20, 32, 39]. No one partic-
ular NSAIDs has been shown to be more effective than another except in the case of 
post-myocardial infarction pericarditis for which aspirin is recommended and other 
NSAIDs should be avoided in order to prevent the disruption of myocardial scar 
formation [40]. Patients taking NSAIDs for pericarditis should concurrently take a 
proton-pump inhibitor for ulcer prophylaxis in the absence of any direct contrain-
dication to do so. Treatment can be tapered once the patient is symptom-free for at 
least 24 hours (typically 1–2 weeks). Alternatively, one study recommends following 
weekly CRP levels along with symptom resolution and beginning tapering, once the 
patient is symptom-free for 24 hours and CRP levels have returned to normal [41].
In 2005, the Colchicine for Acute Pericarditis (COPE) trial suggested colchicine 
as an effective adjunct for treating acute pericarditis when combined with NSAIDs 
therapy for patients with non-bacterial, non-malignancy-related pericardial disease 
[39]. The addition of colchicine was further shown to reduce symptom burden and 
decrease the rate of recurrent pericarditis by a subsequent, randomized-control 
trial (RCT) [42], a finding, which was later supported by a meta-analysis in 2014, 
that demonstrated a reduced risk of recurrence at 18 months in patients undergoing 
treatment for acute pericarditis [43]. The management of acute pericarditis with 
a combination of NSAIDs and colchicine is also currently supported by the 2015 
European Society of Cardiology (ESC) guidelines [2].
For patients with contraindications to NSAIDs therapy (kidney failure, GI bleed-
ing, pregnancy, etc.), glucocorticoids may be used in combination with colchicine 
for the initial treatment of acute pericarditis. Treatment duration is then guided 
by symptom resolution and the normalization of CRP levels with tapering usually 
started 2–4 weeks thereafter. Glucocorticoids have also been utilized in patients 
with pericarditis refractory to NSAIDs and colchicine though one study shows a 
trend toward higher rate of recurrent pericarditis with steroid use [44].
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Geriatric patients appear to have a higher risk of mortality when admitted and 
treated for pericarditis in the hospital. Although data regarding treatment of spe-
cifically elderly patients are sparse, one study examined the relationship between 
pericarditis, age, hospital admission, and mortality. They analyzed 45,504 patients 
above the age of 65 from 1999 to 2012 and found that hospitalization for the treat-
ment of pericarditis is associated with increased risk of 1-year all-cause mortality 
despite a decrease in 1-year mortality rate from 19.7% (95% confidence interval 
(CI) 18.8–20.8) in 1999 to 17.3% (95% CI 15.3–20) in 2012 [45]. While it is possible 
that this association is in part due to a higher prevalence of significant comorbidi-
ties and compromised immune systems among the elderly, it nevertheless remains 
an aspect of pericardial disease that warrants further investigation as advanced 
therapies and support devices continue to enable longer lifespans with time.
4. Recurrent pericarditis
Recurrent pericarditis is a syndrome defined by the reemergence of pericarditis 
after the treatment of the initial inflammatory event [31, 46–48]. A minimum 
4–6 week symptom-free interval post anti-inflammatory treatment is required to 
differentiate recurrent pericarditis from incessant pericarditis.
4.1 Etiology
Acute pericarditis has been found to have recurrence rates as high as 30% in 
patients treated without colchicine [32, 39, 47, 49]. Some cases of recurrent peri-
carditis appear to reflect localized inflammation given the detection of certain 
cytokines (interleukin (IL)-6, IL-8, and interferon gamma) in the pericardial fluid 
and their absence in the serum [50]; however, most cases are considered to be of 
autoimmune etiology [2, 51].
4.2 Clinical presentation
Chest pain appears to be the most common recurring symptom; however, the 
clinical diagnosis of recurrent pericarditis requires the presence of at least one 
of the following in addition to pleuritic chest pain: fever, pericardial rub, ECG 
changes, pericardial effusion, elevated WBC, ESR, CRP, or evidence of active peri-
cardial inflammation on imaging [15]. Patients with previously treated pericarditis 
may experience multiple recurrences over the course of months to years following 
the initial event [52–54].
4.3 Diagnostics
The selection of the initial treatment regimen can directly impact the potential 
for the recurrence of acute pericarditis and may serve as an independent predictor 
of risk. For instance, a prior response to NSAIDs therapy is associated with the 
reduced risk of recurrence [32], whereas treatment with glucocorticoids is associ-
ated with increased recurrence [55]. It is difficult to rely upon ECG changes for the 
diagnosis for recurrent pericarditis as they are non-specific in the majority of cases. 
Chest X-ray and TTE also have limited utility as both will appear to be normal with-
out a significant pericardial effusion. CT and CMRI imaging have proven to be of 
benefit in elucidating the diagnosis of recurrent pericarditis as contrast-enhanced 
CT can detect active pericardial inflammation while CMRI may reveal the evidence 




Recurrent viral or idiopathic pericarditis is typically managed with an outpatient 
medical regimen [2, 52, 54] initially consisting of an NSAIDs and colchicine [15] 
as glucocorticoids are known to increase the risk of recurrence despite multiple 
recurrences of pericarditis [56]. Glucocorticoid therapy is, therefore, reserved for 
patients who are either unable to tolerate NSAIDs or have failed NSAIDs therapy in 
the past [2].
It is important to ensure an adequate trial of NSAIDs was given prior to labeling 
a patient as refractory. Common agents such as Aspirin and Ibuprofen should be 
attempted first followed by Indomethacin for treatment resistant cases. Medication 
should be administered in three doses over 24 hours to ensure consistent therapeutic 
levels, and dosage should be titrated up as needed to achieve symptom control until 
the daily maximum is reached or symptoms have subsided [10, 32, 39, 52, 54, 57].
Patients with recurrent pericarditis are often times designated as refractory to 
colchicine therapy after having received inappropriate dosing or rapid tapers [43]. 
In addition, colchicine should be given twice a day in order to reduce the risk of 
poor compliance due to gastrointestinal discomfort [10, 57, 58].
In cases of recurrent pericarditis refractory to treatment with NSAIDs, col-
chicine, and glucocorticoids, patients found to have the evidence of systemic 
inflammation may benefit from anti-interleukin-1 therapy. A recent trial in 2016 
demonstrated a significant reduction of recurrence (90–18%) in patients with 
pericarditis resistant to colchicine and dependent on corticosteroids with the addi-
tion of anakinra, an IL-1B antagonist [59]. Although promising, this study’s results 
were limited by a small sample size and inconsistent colchicine dosing across trial 
participants warranting further investigation.
5. Constrictive pericarditis
Constrictive pericarditis is a condition that occurs when a thickened or calci-
fied pericardium loses elasticity resulting in the reduction of diastolic filling. It is 
a syndrome that is the end result of chronic pericarditis and pericardial effusion 
gradually progressing to fibrosis [2, 15, 29, 60]. Such impairment overtime causes 
the reduction of pericardial space, which in turn uncouples intrathoracic and intra-
cardiac pressures generating increased interventricular interdependence visible on 
echocardiogram [2, 35, 61, 62].
5.1 Etiology
Constrictive pericarditis can occur as a result of inflammation and effusion 
from any pericardial disease [2, 31, 63]. A combination of studies has found that 
42 to 61% of cases were idiopathic or viral, 11 to 37% postcardiac surgery, 2 to 31% 
postradiation, 3 to 7% due to connective tissue disorders, 3 to 15% bacterial or 
tuberculous, and 1 to 10% related to malignancy, trauma, drug toxicity, sarcoid-
osis, or uremic pericarditis [64–69]. Tuberculosis remains a major global cause of 
constrictive pericarditis especially in endemic nations [2, 70].
5.2 Clinical presentation
Patients with constrictive pericarditis usually present with symptoms of right 
heart failure in the absence of ventricular function impairment. Symptoms are 
consistent with volume overload, such as edema, pleural effusion, dyspnea, ascites, 
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or low output states such as exertional dyspnea and fatigue [2]. As high as 93% 
of patients present with elevated jugular venous pressure (JVP) [65], while only 
approximately 20% of patients present with pulsus paradoxus or Kussmaul’s sign 
[64, 65, 71]. A pericardial knock has been noted in 47% of patients with constrictive 
pericarditis [65].
5.3 Diagnostics
Although the diagnosis of constrictive pericarditis can be made by echocardiog-
raphy [72], an ECG and chest X-ray should also be obtained as part of the initial 
evaluation. There are no specific ECG changes consistently indicative of constrictive 
pericarditis; however, an ECG may be helpful in ruling out other cardiac pathology. 
The chest X-ray may show the evidence of pericardial calcification in which the 
presence of right heart failure would be strongly suggestive of constrictive pericar-
ditis; however, the absence of such a finding would not rule out the disease [2].
All patients with suspected pericardial disease should be evaluated with echo-
cardiography [2, 73]. Septal bounce and pericardial thickening on M-mode and 
2-dimensional echocardiography would be suggestive of a constrictive pattern. On 
Doppler echocardiography, increased interventricular interdependence is associ-
ated with pericardial fibrosis, and the ratio of the right ventricular (RV) area to the 
left ventricular (LV) area, known as systolic area index (SAI), is virtually diagnostic 
of constrictive pericarditis when the SAI is >1.1 [74].
CT imaging can show pericardial thickening and calcification but is not neces-
sary to diagnose constrictive pericarditis. However, the identification of important 
vascular structures on CT can prove useful if planning for pericardiectomy [75]. 
Positron emission tomography (PET)/CT can also be helpful in predicting response 
to corticosteroid therapy [76]. CMRI may show characteristic changes of constric-
tive pericarditis, such as pericardial thickening, dilation of the inferior vena cava, 
or ventricular interdependence, but is usually necessary unless investigating other 
related cardiac pathology.
5.4 Treatment
Treatment of constrictive pericarditis is dependent on the course of the disease 
at the time of evaluation. For early subacute disease in patients who are hemo-
dynamically stable, medical therapy similar to that used for acute pericarditis 
is recommended. Patients who present with the evidence of late chronic disease 
(cachexia, pericardial calcifications, and hepatic dysfunction) or those who have 
failed conservative management with anti-inflammatory therapy can be treated 
with pericardiectomy [63]. The majority of patients achieve symptomatic relief 
with early surgical removal of the inflamed pericardium [69] with one study 
reporting up to 69% of patients being symptom-free at 4 year follow-up [65].
6. Cardiac tamponade
Cardiac tamponade is characterized by the accumulation of pericardial fluid 
causing significant impairment in cardiac function due to the pressure effect of 
external pericardial content causing compression of all cardiac chambers. Increase 
in intrapericardial pressure reduces the myocardial transmural pressure with a 
reduced ventricular wall diastolic compliance and a decrease in cardiac output 
and blood pressure. In cardiac tamponade, unlike constrictive pericarditis, most 
of the inspiratory decline in the intrathoracic pressure is transmitted through 
Inflammatory Heart Diseases
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the pericardium to the right ventricle and results in increased venous return and 
right ventricular distention. The higher intrapericardial pressure limits the right 
ventricular free wall expansion, resulting in bulging of the right ventricular septum 
to the left ventricle. This bulge diminishes the compliance of the left ventricle, 
which results in decreased filling and cardiac output [4, 77]. A similar mechanism 
contributes to pulsus paradoxus, an abnormal decline in systolic blood pressure 
(>10 mmHg) with inspiration. Cardiac tamponade is a treatable cause of cardio-
genic shock that can be rapidly fatal.
Usually, cardiac tamponade is seen after pericarditis, tuberculosis, iatrogenic 
(secondary to cardiac interventions), trauma, neoplasm, with other uncommon 
causes including, collagen vascular disorder, radiation therapy, post-myocardial 
infarction, uremia, aortic dissection, and a bacterial infection.
6.1 Etiology
Cardiac tamponade could be acute, subacute, low-pressure type, or regional. 
Acute cardiac tamponade is sudden in onset and acutely life-threatening if not 
treated. Subacute cardiac tamponade is less dramatic compared to acute, but once 
the intrapericardial pressure reaches the threshold, patients experience classi-
cal tamponade symptoms related to decreased cardiac function. Low-pressure 
tamponade is a condition that appears in hypovolemic patients (such as traumatic 
hemorrhage, over diuresis, etc.). Correction of volume status reveals a typical tam-
ponade pattern. Regional tamponade occurs from loculated effusion or a localized 
hematoma causing compression of only selected chambers. It is usually seen after 
myocardial infarction or pericardiotomy [77].
6.2 Clinical presentation
Depending on the severity of the tamponade, a variety of clinical findings are 
seen. Sinus tachycardia as a physiologic response to maintain the cardiac output is 
common. Elevated jugular venous pressure, muffled heart sounds, and systemic 
hypotension together referred to as Beck’s triad is a pathognomonic sign for 
tamponade.
6.3 Diagnosis
The diagnostic approach and the evaluation of cardiac tamponade are similar 
to that for patients with suspected pericardial effusion. The ECG findings include 
sinus tachycardia, low voltage of QRS complex, and frequently electrical alternans, 
which is beat-to-beat changes in the position of the heart with relation to cardiac 
tamponade. The presence of total electrical alternans, including P wave, QRS 
complex, and ST segment alternans, is highly specific for cardiac tamponade, but 
sensitivity is very low with findings present in only 5–10% of cases. The presence 
of lone QRS alternans is more common but is not very specific for tamponade. The 
presence of QRS vector alternans (axis shift) is more specific than QRS amplitude 
alternans for the cardiac tamponade [77, 78].
TTE is the standard first-line imaging technique recommended for the evalu-
ation of cardiac tamponade with excellent safety and efficacy. The size of the 
pericardial effusion does not indicate significance. Since respiration has an impact 
on intracardiac pressures, mainly on the right side of the heart, this respirophasic 
flow pattern becomes more evident in tamponade, which can be measured by 
Doppler echocardiographic variations in blood flow across the mitral (>25% varia-
tion) (Figure 3) and tricuspid valves (>40% variation) as well as pulmonary and 
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systemic outflow. Right atrial collapse and RV collapse on diastole (Figure 4) are 
usual signs of cardiac tamponade, but in the setting of severe pulmonary hyperten-
sion, right-sided chamber collapse may be delayed and preceded by left atrial col-
lapse. In most cases, the thickness of the left ventricular wall and lower compliance 
prevents LV collapse. As the tamponade worsens, there are progressive impairments 
in hemodynamics and intracardiac flows. Elevated pressures in the right atrium can 
Figure 3. 
Doppler echocardiographic variations in blood flow across the mitral valve.
Figure 4. 




be assessed from a plethora of the inferior vena cava (IVC) which is a lack of change 
in IVC caliber in response to respiratory flow pattern (<50% reduction in IVC diam-
eter during inspiration). The swinging movement of the heart within the pericar-
dial sac is another echocardiographic sign. These TTE findings in cardiac structural 
and functional change with a decline in cardiac function often occur well before 
the onset of pulsus paradoxus and significant clinical deterioration, and thus, they 
are an important indicator in cardiac tamponade [11, 79]. Cardiac CT and CMRI 
may provide valuable information about the functional and structural change of 
the heart and pericardium, but they are only required in special conditions such as 
localized tamponade, loculated pericardial effusion, or hematoma [61, 79].
6.4 Treatment
The treatment of cardiac tamponade is decompression with pericardiocentesis 
which can be done by percutaneous catheter pericardiocentesis or open surgical 
drainage with or without a pericardial window or video-assisted thoracoscopic 
pericardiectomy. Catheter pericardiocentesis under echocardiographic or fluoro-
scopic guidance is a more rapid and less invasive technique. Surgical pericardiocen-
tesis is usually performed in purulent pericarditis bleeding into the pericardium or 
when pericardial biopsies and pericardiectomy are needed [2, 77]. A triage system 
proposed by the ESC Working Group on Myocardial and Pericardial Diseases can be 
used to guide the timing of the pericardiocentesis in non-emergent cases [80]. Fluid 
removal and decompression of the pericardial cavity rapidly improve the clinical 
hemodynamic status. Positive pressure mechanical ventilation should be avoided 
as it increases the intrathoracic pressure that deteriorates cardiac filling. The use of 
vasodilators and diuretics that reduce the preload is not recommended in the pres-
ence of cardiac tamponade [2].
Disclosure
None of the authors have any conflicts of interest to disclose.
Author details
Ammar Athar†, Kartik Dhaduk† and Wilbert S. Aronow*
Cardiology Division, Department of Medicine, Westchester Medical Center and 
New York Medical College, NY, USA
*Address all correspondence to: wsaronow@aol.com
† These authors are contributed equally.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
15
Pericardial Diseases in Elderly Patients
DOI: http://dx.doi.org/10.5772/intechopen.89473
[1] Sizeland KH, Wells HC, Higgins J, 
Cunanan CM, Kirby N, Hawley A, et al. 
Age dependent differences in collagen 
alignment of glutaraldehyde fixed 
bovine pericardium. BioMed Research 
International. 2014;2014:189197
[2] Adler Y, Charron P, Imazio M, 
Badano L, Baron-Esquivias G, 
Bogaert J, et al. 2015 ESC guidelines 
for the diagnosis and management of 
pericardial diseases: The task force 
for the diagnosis and Management of 
Pericardial Diseases of the European 
Society of Cardiology (ESC) endorsed 
by: The European Association 
for Cardio-Thoracic Surgery 
(EACTS). European Heart Journal. 
2015;36(42):2921-2964
[3] Imazio M, Adler Y. Management of 
pericardial effusion. European Heart 
Journal. 2013;34(16):1186-1197
[4] Shabetai R. Pericardial effusion: 
haemodynamic spectrum. Heart. 
2004;90(3):255-256
[5] Sagrista-Sauleda J, 
Merce J, Permanyer-Miralda G, 
Soler-Soler J. Clinical clues to the 
causes of large pericardial effusions. 
The American Journal of Medicine. 
2000;109(2):95-101
[6] Merce J, Sagrista Sauleda J, Permanyer 
Miralda G, Carballo J, Olona M, 
Soler Soler J. Pericardial effusion in 
the elderly: A different disease? 
Revista Española de Cardiología. 
2000;53(11):1432-1436
[7] Sagrista-Sauleda J, 
Merce AS, Soler-Soler J. Diagnosis 
and management of pericardial 
effusion. World Journal of Cardiology. 
2011;3(5):135-143
[8] Khandaker MH, Espinosa RE, 
Nishimura RA, Sinak LJ, Hayes SN, 
Melduni RM, et al. Pericardial disease: 
Diagnosis and management. Mayo 
Clinic Proceedings. 2010;85(6):572-593
[9] Sarkar M, Bhardwaj R, Madabhavi I, 
Gowda S, Dogra K. Pulsus paradoxus. 
The Clinical Respiratory Journal. 
2018;12(8):2321-2331
[10] Imazio M, Spodick DH, Brucato A, 
Trinchero R, Adler Y. Controversial 
issues in the management of 
pericardial diseases. Circulation. 
2010;121(7):916-928
[11] Yared K, Baggish AL, Picard MH, 
Hoffmann U, Hung J. Multimodality 
imaging of pericardial diseases. 
JACC: Cardiovascular Imaging. 
2010;3(6):650-660
[12] De Filippo O, Gatti P, Rettegno S, 
Iannaccone M, D’Ascenzo F, Lazaros G, 
et al. Is pericardial effusion a negative 
prognostic marker? Meta-analysis 
of outcomes of pericardial effusion. 
Journal of Cardiovascular Medicine. 
2019;20(1):39-45
[13] Spodick D. The Pericardium, a 
Comprehensive Textbook. New York: 
Marcel Dekker; 1997. p. 260
[14] Spodick D. Pericardial disease. 
In: Braunwald E, Zipes D, Libby P, 
editors. Heart Disease: A Textbook of 
Cardiovascular Medicine. New York: 
Saunders; 2001. p. 183
[15] Imazio M, Gaita F, LeWinter M.  
Evaluation and treatment of 
pericarditis: A systematic review. 
Journal of the American Medical 
Association. 2015;314(14):1498-1506
[16] Heidenreich PA, Eisenberg MJ, 
Kee LL, Somelofski CA, Hollander H, 
Schiller NB, et al. Pericardial effusion 
in AIDS. Incidence and survival. 
Circulation. 1995;92(11):3229-3234
[17] Chen Y, Brennessel D, Walters J, 





pericardial effusion: Report of 40 cases 
and review of the literature. American 
Heart Journal. 1999;137(3):516-521
[18] Levy PY, Corey R, Berger P, 
Habib G, Bonnet JL, Levy S, 
et al. Etiologic diagnosis of 204 
pericardial effusions. Medicine. 
2003;82(6):385-391
[19] Permanyer-Miralda G, 
Sagrista-Sauleda J, Soler-Soler J. Primary 
acute pericardial disease: A prospective 
series of 231 consecutive patients. 
The American Journal of Cardiology. 
1985;56(10):623-630
[20] Zayas R, Anguita M, Torres F, 
Gimenez D, Bergillos F, Ruiz M, et al. 
Incidence of specific etiology and 
role of methods for specific etiologic 
diagnosis of primary acute pericarditis. 
The American Journal of Cardiology. 
1995;75(5):378-382
[21] Galve E, Garcia-Del-Castillo H, 
Evangelista A, Batlle J, Permanyer- 
Miralda G, Soler-Soler J. Pericardial 
effusion in the course of myocardial 
infarction: Incidence, natural history, 
and clinical relevance. Circulation. 
1986;73(2):294-299
[22] Correale E, Maggioni AP, 
Romano S, Ricciardiello V, Battista R, 
Salvarola G, et al. Comparison of 
frequency, diagnostic and prognostic 
significance of pericardial involvement 
in acute myocardial infarction treated 
with and without thrombolytics. 
Gruppo Italiano per lo studio della 
Sopravvivenza nell’Infarto Miocardico 
(GISSI). The American Journal of 
Cardiology. 1993;71(16):1377-1381
[23] Belkin RN, Mark DB, Aronson L, 
Szwed H, Califf RM, Kisslo J. Pericardial 
effusion after intravenous recombinant 
tissue-type plasminogen activator 
for acute myocardial infarction. The 
American Journal of Cardiology. 
1991;67(6):496-500
[24] Shahar A, Hod H, Barabash GM, 
Kaplinsky E, Motro M. Disappearance 
of a syndrome: Dressler’s syndrome in 
the era of thrombolysis. Cardiology. 
1994;85(3-4):255-258
[25] Stewart JR, Fajardo LF, Gillette SM, 
Constine LS. Radiation injury to 
the heart. International Journal of 
Radiation Oncology, Biology, Physics. 
1995;31(5):1205-1211
[26] Rostand SG, Rutsky EA. Pericarditis 
in end-stage renal disease. Cardiology 
Clinics. 1990;8(4):701-707
[27] Gunukula SR, Spodick DH. 
Pericardial disease in renal 
patients. Seminars in Nephrology. 
2001;21(1):52-56
[28] Kabadi UM, Kumar SP. Pericardial 
effusion in primary hypothyroidism. 
American Heart Journal. 1990;120 
(6 Pt 1):1393-1395
[29] Imazio M. Myopericardial Diseases. 
New York: Springer; 2016
[30] Spodick DH. Acute pericarditis: 
Current concepts and practice. Journal 
of the American Medical Association. 
2003;289(9):1150-1153
[31] Troughton RW, Asher CR, 
Klein AL. Pericarditis. Lancet. 
2004;363(9410):717-727
[32] Imazio M, Demichelis B, Parrini I, 
Giuggia M, Cecchi E, Gaschino G, et al. 
Day-hospital treatment of acute 
pericarditis: A management program 
for outpatient therapy. Journal of 
the American College of Cardiology. 
2004;43(6):1042-1046
[33] Imazio M, Cecchi E, Demichelis B, 
Ierna S, Demarie D, Ghisio A, et al. 
Indicators of poor prognosis of acute 
pericarditis. Circulation. 2007;115(21): 
2739-2744
[34] Imazio M, Demichelis B, Cecchi E, 
Belli R, Ghisio A, Bobbio M, et al. Cardiac 
17
Pericardial Diseases in Elderly Patients
DOI: http://dx.doi.org/10.5772/intechopen.89473
troponin I in acute pericarditis. Journal 
of the American College of Cardiology. 
2003;42(12):2144-2148
[35] Klein AL, Abbara S, Agler DA, 
Appleton CP, Asher CR, Hoit B, et al. 
American Society of Echocardiography 
clinical recommendations for 
multimodality cardiovascular 
imaging of patients with pericardial 
disease: Endorsed by the Society for 
Cardiovascular Magnetic Resonance 
and Society of cardiovascular 
computed tomography. Journal of the 
American Society of Echocardiography. 
2013;26(9):965-1012.e15
[36] Rutsky EA, Rostand SG. Pericarditis 
in end-stage renal disease: Clinical 
characteristics and management. 
Seminars in Dialysis. 1989;2(1):25-30
[37] Spodick DH. Arrhythmias during 
acute pericarditis. A prospective study 
of 100 consecutive cases. Journal of 
the American Medical Association. 
1976;235(1):39-41
[38] Imazio M, Cecchi E, Demichelis B, 
Chinaglia A, Ierna S, Demarie D, et al. 
Myopericarditis versus viral or 
idiopathic acute pericarditis. Heart. 
2008;94(4):498-501
[39] Imazio M, Bobbio M, Cecchi E, 
Demarie D, Demichelis B, Pomari F, et al. 
Colchicine in addition to conventional 
therapy for acute pericarditis: 
Results of the COlchicine for acute 
PEricarditis (COPE) trial. Circulation. 
2005;112(13):2012-2016
[40] Hammerman H, Alker KJ, 
Schoen FJ, Kloner RA. Morphologic 
and functional effects of piroxicam 
on myocardial scar formation after 
coronary occlusion in dogs. The 
American Journal of Cardiology. 
1984;53(4):604-607
[41] Imazio M, Brucato A, Maestroni S, 
Cumetti D, Dominelli A, Natale G, 
et al. Prevalence of C-reactive protein 
elevation and time course of 
normalization in acute pericarditis: 
Implications for the diagnosis, 
therapy, and prognosis of pericarditis. 
Circulation. 2011;123(10):1092-1097
[42] Imazio M, Cecchi E, Ierna S, 
Trinchero R, ICAP Investigators. 
Investigation on colchicine for acute 
pericarditis: A multicenter randomized 
placebo-controlled trial evaluating 
the clinical benefits of colchicine 
as adjunct to conventional therapy 
in the treatment and prevention of 
pericarditis; study design amd rationale. 
Journal of Cardiovascular Medicine. 
2007;8(8):613-617
[43] Alabed S, Cabello JB, Irving GJ, 
Qintar M, Burls A. Colchicine for 
pericarditis. Cochrane Database of 
Systematic Reviews. 2014;8:CD010652. 
DOI: 10.1002/14651858.CD010652.
pub2
[44] Lotrionte M, Biondi-Zoccai G, 
Imazio M, Castagno D, Moretti C, 
Abbate A, et al. International 
collaborative systematic review 
of controlled clinical trials on 
pharmacologic treatments for acute 
pericarditis and its recurrences. 
American Heart Journal. 
2010;160(4):662-670
[45] Mody P, Bikdeli B, Wang Y, 
Imazio M, Krumholz HM. Trends in 
acute pericarditis hospitalizations and 
outcomes among the elderly in the USA, 
1999-2012. European Heart Journal—
Quality of Care and Clinical Outcomes. 
2018;4(2):98-105
[46] Robinson J, Brigden W. Recurrent 
pericarditis. British Medical Journal. 
1968;2(5600):272-275
[47] Fowler NO. Recurrent pericarditis. 
Cardiology Clinics. 1990;8(4):621-626
[48] Fowler NO, Harbin AD 3rd. 
Recurrent acute pericarditis: Follow-up 
study of 31 patients. Journal of the 
Inflammatory Heart Diseases
18
American College of Cardiology. 
1986;7(2):300-305
[49] Maisch B, Ristic AD, Pankuweit S. 
Intrapericardial treatment of 
autoreactive pericardial effusion with 
triamcinolone; the way to avoid side 
effects of systemic corticosteroid 
therapy. European Heart Journal. 
2002;23(19):1503-1508
[50] Pankuweit S, Wadlich A, Meyer E, 
Portig I, Hufnagel G, Maisch B. Cytokine 
activation in pericardial fluids in 
different forms of pericarditis. Herz. 
2000;25(8):748-754
[51] Brucato A, Brambilla G, Moreo A, 
Alberti A, Munforti C, Ghirardello A, 
et al. Long-term outcomes in difficult-
to-treat patients with recurrent 
pericarditis. The American Journal of 
Cardiology. 2006;98(2):267-271
[52] Imazio M, Bobbio M, Cecchi E, 
Demarie D, Pomari F, Moratti M, et al. 
Colchicine as first-choice therapy 
for recurrent pericarditis: Results of 
the CORE (COlchicine for REcurrent 
pericarditis) trial. Archives of Internal 
Medicine. 2005;165(17):1987-1991
[53] Soler-Soler J, Sagrista-Sauleda J, 
Permanyer-Miralda G. Relapsing 
pericarditis. Heart. 2004;90(11): 
1364-1368
[54] Imazio M, Demichelis B, Parrini I, 
Cecchi E, Demarie D, Ghisio A, et al. 
Management, risk factors, and 
outcomes in recurrent pericarditis. 
The American Journal of Cardiology. 
2005;96(5):736-739
[55] Lange RA, Hillis LD. Clinical 
practice. Acute pericarditis. The 
New England Journal of Medicine. 
2004;351(21):2195-2202
[56] Artom G, Koren-Morag N, 
Spodick DH, Brucato A, Guindo J, 
Bayes-de-Luna A, et al. Pretreatment 
with corticosteroids attenuates the 
efficacy of colchicine in preventing 
recurrent pericarditis: A multi-centre 
all-case analysis. European Heart 
Journal. 2005;26(7):723-727
[57] Imazio M, Brucato A, Mayosi BM, 
Derosa FG, Lestuzzi C, Macor A, et al. 
Medical therapy of pericardial diseases: 
Part I: Idiopathic and infectious 
pericarditis. Journal of Cardiovascular 
Medicine. 2010;11(10):712-722
[58] Markel G, Imazio M, 
Brucato A, Adler Y. Prevention of 
recurrent pericarditis with colchicine 
in 2012. Clinical Cardiology. 
2013;36(3):125-128
[59] Brucato A, Imazio M, Gattorno M, 
Lazaros G, Maestroni S, Carraro M, 
et al. Effect of anakinra on recurrent 
pericarditis among patients with 
colchicine resistance and corticosteroid 
dependence: The AIRTRIP 
randomized clinical trial. Journal of 
the American Medical Association. 
2016;316(18):1906-1912
[60] LeWinter M, Imazio M. Pericardial 
disease. In: Braunwald E, 
Zipes D, Libby P, editors. Heart Disease: 
A Textbook of Cardiovascular Medicine. 
New York: Saunders; 2018
[61] Cosyns B, Plein S, 
Nihoyanopoulos P, Smiseth O, 
Achenbach S, Andrade MJ, et al. European 
Association of Cardiovascular Imaging 
(EACVI) position paper: Multimodality 
imaging in pericardial disease. European 
Heart Journal Cardiovascular Imaging. 
2015;16(1):12-31
[62] Imazio M, Pedrotti P, Quattrocchi G, 
Roghi A, Badano L, Faletti R, et al. 
Multimodality imaging of pericardial 
diseases. Journal of Cardiovascular 
Medicine. 2016;17(11):774-782
[63] Welch TD. Constrictive pericarditis: 
Diagnosis, management and clinical 
outcomes. Heart. 2018;104(9):725-731
19
Pericardial Diseases in Elderly Patients
DOI: http://dx.doi.org/10.5772/intechopen.89473
[64] Cameron J, Oesterle SN, 
Baldwin JC, Hancock EW. The etiologic 
spectrum of constrictive pericarditis. 
American Heart Journal. 1987;113 
(2 Pt 1):354-360
[65] Ling LH, Oh JK, Schaff HV, 
Danielson GK, Mahoney DW, Seward JB, 
et al. Constrictive pericarditis in the 
modern era: Evolving clinical spectrum 
and impact on outcome after 
pericardiectomy. Circulation. 
1999;100(13):1380-1386
[66] Bertog SC, Thambidorai SK, 
Parakh K, Schoenhagen P, Ozduran V, 
Houghtaling PL, et al. Constrictive 
pericarditis: Etiology and cause-specific 
survival after pericardiectomy. Journal 
of the American College of Cardiology. 
2004;43(8):1445-1452
[67] Szabo G, Schmack B, Bulut C, 
Soos P, Weymann A, Stadtfeld S, et al. 
Constrictive pericarditis: Risks, 
aetiologies and outcomes after total 
pericardiectomy: 24 years of experience. 
European Journal of Cardio-Thoracic 
Surgery. 2013;44(6):1023-1028; 
discussion 1028
[68] George TJ, Arnaoutakis GJ, 
Beaty CA, Kilic A, Baumgartner WA, 
Conte JV. Contemporary etiologies, 
risk factors, and outcomes after 
pericardiectomy. The Annals of 
Thoracic Surgery. 2012;94(2):445-451
[69] Vistarini N, Chen C, Mazine A, 
Bouchard D, Hebert Y, Carrier M, 
et al. Pericardiectomy for constrictive 
pericarditis: 20 years of experience 
at the Montreal heart institute. 
The Annals of Thoracic Surgery. 
2015;100(1):107-113
[70] Mutyaba AK, Balkaran S, Cloete R, 
du Plessis N, Badri M, Brink J, et al. 
Constrictive pericarditis requiring 
pericardiectomy at Groote Schuur 
hospital, Cape Town, South Africa: 
Causes and perioperative outcomes in 
the HIV era (1990-2012). The Journal of 
Thoracic and Cardiovascular Surgery. 
2014;148(6):3058-65.e1
[71] Spodick DH. The normal and 
diseased pericardium: Current 
concepts of pericardial physiology, 
diagnosis and treatment. Journal of 
the American College of Cardiology. 
1983;1(1):240-251
[72] Welch TD, Ling LH, Espinosa RE, 
Anavekar NS, Wiste HJ, Lahr BD, 
et al. Echocardiographic diagnosis of 
constrictive pericarditis: Mayo Clinic 
criteria. Circulation. Cardiovascular 
Imaging. 2014;7(3):526-534
[73] Cheitlin MD, Armstrong WF, 
Aurigemma GP, Beller GA, Bierman FZ, 
Davis JL, et al. ACC/AHA/ASE 2003 
guideline update for the clinical 
application of echocardiography: 
Summary article: A report of the 
American College of Cardiology/
American Heart Association task force 
on practice guidelines (ACC/AHA/
ASE Committee to update the 1997 
guidelines for the clinical application 
of echocardiography). Circulation. 
2003;108(9):1146-1162
[74] Talreja DR, Nishimura RA, 
Oh JK, Holmes DR. Constrictive 
pericarditis in the modern era: Novel 
criteria for diagnosis in the cardiac 
catheterization laboratory. Journal of 
the American College of Cardiology. 
2008;51(3):315-319
[75] Verhaert D, Gabriel RS, Johnston D, 
Lytle BW, Desai MY, Klein AL. The 
role of multimodality imaging in the 
management of pericardial disease. 
Circulation. Cardiovascular Imaging. 
2010;3(3):333-343
[76] Chang SA, Choi JY, Kim EK, 
Hyun SH, Jang SY, Choi JO, et al. 
[18F]Fluorodeoxyglucose PET/CT 
predicts response to steroid therapy 
in constrictive pericarditis. Journal of 




[77] Spodick DH. Acute cardiac 
tamponade. The New England Journal 
of Medicine. 2003;349(7):684-690
[78] Adlam DFJ. Pericardial disease. 
Medicine. 2018;46(11):703-708
[79] Restrepo CS, Lemos DF, 
Lemos JA, Velasquez E, Diethelm L, 
Ovella TA, et al. Imaging findings 
in cardiac tamponade with 
emphasis on CT. Radiographics. 
2007;27(6):1595-1610
[80] Ristic AD, Imazio M, 
Adler Y, Anastasakis A, Badano LP, 
Brucato A, et al. Triage strategy 
for urgent management of cardiac 
tamponade: A position statement of 
the European Society of Cardiology 
Working Group on myocardial and 
pericardial diseases. European Heart 
Journal. 2014;35(34):2279-2284
